Menu Search
Equities

YiChang HEC ChangJiang Pharmaceutical Co Ltd

1558:HKG

YiChang HEC ChangJiang Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)9.34
  • Today's Change-0.20 / -2.10%
  • Shares traded1.35m
  • 1 Year change+7.60%
  • Beta0.8764
Data delayed at least 15 minutes, as of Nov 22 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year YiChang HEC ChangJiang Pharmaceutical Co Ltd grew revenues 68.08% from 3.74bn to 6.29bn while net income improved 2,501.23% from 76.60m to 1.99bn.
Gross margin78.90%
Net profit margin27.37%
Operating margin32.91%
Return on assets11.69%
Return on equity21.15%
Return on investment17.27%
More ▼

Cash flow in CNYView more

In 2023, YiChang HEC ChangJiang Pharmaceutical Co Ltd increased its cash reserves by 81.30%, or 750.87m. The company earned 1.67bn from its operations for a Cash Flow Margin of 26.58%. In addition the company generated 554.57m cash from investing, though they paid out 1.48bn more in financing than they received.
Cash flow per share2.34
Price/Cash flow per share4.09
Book value per share10.58
Tangible book value per share7.45
More ▼

Balance sheet in CNYView more

YiChang HEC ChangJiang Pharmaceutical Co Ltd has a Debt to Total Capital ratio of 21.26%, a higher figure than the previous year's 7.33%.
Current ratio2.15
Quick ratio1.93
Total debt/total equity0.270
Total debt/total capital0.2126
More ▼

Growth rates in CNY

Year on year, growth in earnings per share excluding extraordinary items increased 2,501.30%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
EPS growth(5 years)16.78
EPS (TTM) vs
TTM 1 year ago		44.69
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.